COMPREHENSIVE MEDICINAL CHEMISTRY III

The trailblazing scientific discoveries of the 21st century have brought new opportunities for drug discovery research. The discipline of medicinal chemistry continues to evolve as it adapts to these new opportunities and strives to solve new challenges. Covered in the new edition are not only the breakthrough therapies of the past decade in cancer, hepatitis C, heart failure, dyslipidemia, cystic fibrosis, multiple sclerosis, HIV, etc., but also extensive discussion of new business models in drug discovery research, shifting industry demographics, emerging technologies, in silico drug discovery tools, experimental ADME and toxicology, and biologics medicine. The tone of this edition is prospective in which contributors identify outstanding issues and paths forward in their area of expertise. The aim is to provide drug discovery scientists in industry, government, academia, and research organizations with a contemporary global perspective on the field that includes a look ahead in selected areas. The eight individual volumes fulfill these objectives and include extensive discussion of biomolecular therapeutics, drug targeting and delivery, development of chemical biology tools, data collection and analysis, in silico models as predictors for biological properties, identification/validation of new targets, approaches to quantify target engagement, new methods for synthesis of drug candidates such as green chemistry, development of novel scaffolds for drug discovery, and the role of regulatory agencies in drug discovery.